Sonidegib (Odomzo) for Basal Cell Carcinoma - Details


( Last Updated : April 29, 2021)
Generic Name:
Sonidegib
Project Status:
Active
Therapeutic Area:
Basal Cell Carcinoma
Manufacturer:
Sun Pharma Canada Inc.
Brand Name:
Odomzo
Project Line:
Reimbursement Review
Project Number:
PC0215-000
NOC Date:

Details


Strength:
200 mg
Tumour Type:
Skin and Melanoma
Indications:
Basal Cell Carcinoma (BCC)
Funding Request:
For the treatment of adult patients with histologically confirmed locally advanced basal cell carcinoma (laBCC) that is not amenable to radiation therapy or curative surgery.
Review Status:
Notification to Implement Issued
Sponsor:
Sun Pharma Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Funding Request:
For the treatment of adult patients with histologically confirmed locally advanced basal cell carcinoma (laBCC) that is not amenable to radiation therapy or curative surgery.
pERC Meeting:
Final Recommendation Issued: